Literature DB >> 6601625

Activation of macrophages for microbicidal and tumoricidal effector functions by soluble factors from EL-4, a continuous T cell line.

C A Nacy, S L James, W R Benjamin, J J Farrar, W T Hockmeyer, M S Meltzer.   

Abstract

Macrophages treated with culture fluids from EL-4 cells, a continuous T cell line, were activated to kill mKSA-TU-5 fibrosarcoma cells, amastigotes of Leishmania tropica, and schistosomula of Schistosoma mansoni. Active EL-4 factors eluted from Sephadex G-100 in two distinct regions: molecular weight 45,000 (activities induced killing of unrelated intracellular and extracellular targets) and molecular weight 23,000 (activities induced killing of extracellular targets only). These results confirm heterogeneity among activation signals for the induction of macrophage microbicidal and tumoricidal activities. Factors that induced cytocidal activity against extracellular tumor cells and schistosomula were distinct from those that induced destruction of intracellular amastigotes.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6601625      PMCID: PMC264928          DOI: 10.1128/iai.40.2.820-824.1983

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  16 in total

1.  Biological studies of interferon. I. Suppression of cellular infection with eastern equine encephalomyelitis virus.

Authors:  R R WAGNER
Journal:  Virology       Date:  1961-03       Impact factor: 3.616

2.  Defective tumoricidal capacity of macrophages from A/J mice. II. Comparison of the macrophage cytotoxic defect of A/J mice with that of lipid A-unresponsive C3H/HeJ mice.

Authors:  D Boraschi; M S Meltzer
Journal:  J Immunol       Date:  1979-04       Impact factor: 5.422

3.  Macrophage activation for tumor cytotoxicity: genetic variation in macrophage tumoricidal capacity among mouse strains.

Authors:  D Boraschi; M S Meltzer
Journal:  Cell Immunol       Date:  1979-06       Impact factor: 4.868

4.  Macrophage activation for tumor cytotoxicity: induction of tumoricidal macrophages by supernatants of PPD-stimulated Bacillus Calmette-Guérin-immune spleen cell cultures.

Authors:  L P Ruco; M S Meltzer
Journal:  J Immunol       Date:  1977-09       Impact factor: 5.422

5.  Interaction of Bacillus Calmette--Guérin-activated macrophages and neoplastic cells in vitro. I. Conditions of binding and its selectivity.

Authors:  P A Marino; D O Adams
Journal:  Cell Immunol       Date:  1980-08-15       Impact factor: 4.868

6.  Macrophage activation for tumor cytotoxicity: control of macrophage tumoricidal capacity by the LPS gene.

Authors:  L P Ruco; M S Meltzer; D L Rosenstreich
Journal:  J Immunol       Date:  1978-08       Impact factor: 5.422

7.  Macrophage activation for tumor cytotoxicity: development of macrophage cytotoxic activity requires completion of a sequence of short-lived intermediary reactions.

Authors:  L P Ruco; M S Meltzer
Journal:  J Immunol       Date:  1978-11       Impact factor: 5.422

8.  Macrophages in resistance to rickettsial infections: characterization of lymphokines that induce rickettsiacidal activity in macrophages.

Authors:  C A Nacy; E J Leonard; M S Meltzer
Journal:  J Immunol       Date:  1981-01       Impact factor: 5.422

9.  Macrophages in resistance to rickettsial infection: macrophage activation in vitro for killing of Rickettsia tsutsugamushi.

Authors:  C A Nacy; M S Meltzer
Journal:  J Immunol       Date:  1979-12       Impact factor: 5.422

10.  Extracellular cytolysis by activated macrophages and granulocytes. I. Pharmacologic triggering of effector cells and the release of hydrogen peroxide.

Authors:  C F Nathan; L H Brukner; S C Silverstein; Z A Cohn
Journal:  J Exp Med       Date:  1979-01-01       Impact factor: 14.307

View more
  14 in total

1.  Induction of tryptophan catabolism is the mechanism for gamma-interferon-mediated inhibition of intracellular Chlamydia psittaci replication in T24 cells.

Authors:  G I Byrne; L K Lehmann; G J Landry
Journal:  Infect Immun       Date:  1986-08       Impact factor: 3.441

2.  Potentiation of direct antitumor cytotoxicity and production of tumor cytolytic factors in human blood monocytes by human recombinant interferon-gamma and muramyl dipeptide derivatives.

Authors:  S Sone; G Lopez-Berestein; I J Fidler
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

Review 3.  Macrophage-directed lymphokines.

Authors:  D Y Liu
Journal:  Surv Immunol Res       Date:  1984

4.  Gamma interferon reverses inhibition of leukocyte bactericidal activity by a 25-kilodalton fraction from Mycobacterium tuberculosis.

Authors:  A A Wadee; J D Cohen; A R Rabson
Journal:  Infect Immun       Date:  1987-11       Impact factor: 3.441

Review 5.  Interferons and indoleamine 2,3-dioxygenase: role in antimicrobial and antitumor effects.

Authors:  J M Carlin; Y Ozaki; G I Byrne; R R Brown; E C Borden
Journal:  Experientia       Date:  1989-06-15

6.  T-cell hybridoma-produced lymphokine that activates macrophages to suppress intracellular growth of Histoplasma capsulatum.

Authors:  B Wu-Hsieh; A Zlotnik; D H Howard
Journal:  Infect Immun       Date:  1984-01       Impact factor: 3.441

7.  Recombinant and natural gamma-interferon activation of macrophages in vitro: different dose requirements for induction of killing activity against phagocytizable and nonphagocytizable fungi.

Authors:  E Brummer; C J Morrison; D A Stevens
Journal:  Infect Immun       Date:  1985-09       Impact factor: 3.441

Review 8.  The role of T cell--macrophage interactions in tuberculosis.

Authors:  S H Kaufmann; I E Flesch
Journal:  Springer Semin Immunopathol       Date:  1988

9.  Capacity of recombinant gamma interferon to activate macrophages for Salmonella-killing activity.

Authors:  K Kagaya; K Watanabe; Y Fukazawa
Journal:  Infect Immun       Date:  1989-02       Impact factor: 3.441

10.  Production of and in vitro response to interleukin 2 in the acquired immunodeficiency syndrome.

Authors:  H W Murray; K Welte; J L Jacobs; B Y Rubin; R Mertelsmann; R B Roberts
Journal:  J Clin Invest       Date:  1985-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.